Baird downgraded Maravai Lifesciences (MRVI) to Neutral from Outperform with a price target of $3, down from $9, after the company announced ...

In a report released today, Matt Larew from William Blair maintained a Hold rating on Maravai Lifesciences Holdings (MRVI – Research Report).

Law Offices of Howard G. Smith announces an investigation on behalf of Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ: MRVI) investors concerning the Company's possible ...

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to ...

Shares of Maravai LifeSciences (NASDAQ:MRVI) dipped over 15% premarket on Tuesday after the company said it is postponing its earnings release and call scheduled for today (Feb. 25, 2025). The life ...

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced ...

Maravai LifeSciences Holdings (NASDAQ:MRVI) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is -$0.04 (+95.0% Y/Y) and the ...

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stock fell 15% after the company announced it is postponing its fourth quarter and full year 2024 earnings release and conference call. The life ...

NASDAQ:MRVI opened at $4.11 on Friday. Maravai LifeSciences has a one year low of $3.93 and a one year high of $11.56. The stock has a market cap of $1.04 billion, a P/E ratio of -2.51 and a beta ...

1 Day MRVI 4.05% DJIA -1.69% S&P Mid Cap 400 -2.40% Health Care/Life Sciences -0.37% ...